Core Business

  

Biopharma CDMO Services

  
Website

Mycenax Biotech Inc.

Mycenax (Stock code: 4726.TW)  is a CDMO (Contract Development and Manufacturing Organization) company that provides biopharmaceutical services and solutions for drug development and production, with customers in Taiwan, Japan, Korea, Singapore, among other Asia-Pacific regions, as well as Europe and the United States.
With a basis in the production of biosimilars and new biopharmaceuticals, since 2019 Mycenax has shifted to advancing technology platforms as well as building and expanding GMP plants to meet international standards, fulfilling the diverse needs of customers and providing tailor-made and streamlined CDMO services.

Taiwan

News
Date Title
2023-07-19 BIO Asia–Taiwan 2023 亞洲生技大會來了!晟德集團打造台灣生技波克夏 聚焦CDMO、AI、高階醫材 立足台灣 放眼世界 Detail
2023-12-05 晟德法說》釋「長線」佳音 展望明年景氣持樂觀看法 Detail
2024-06-25 晟德股東會/承認配發1.5元現金股利 殖利率3.3% 連續24年配發股利 2024年成長充滿信心 續替股東創造最大價值 Detail
2024-07-19 林榮錦打造晟德生技投資帝國 Detail
2024-08-13 晟德(4123)Q2財報新聞稿 Detail